Basiliximab (Simulect, Chimeric) is an MAb produced by amouse monoclonal cell line that has been engineered to producethe basiliximab IgG1 κ antibody glycoprotein. Theproduct is chimeric (murine/human). Basiliximab is indicatedfor prophylaxis of acute organ rejection in patients receivingrenal transplantation when used as part of a regimenof immunosuppressants and corticosteroids. Basiliximab isalso indicated in pediatric renal transplantation.Basiliximab specifically binds to the IL-2 receptor α-chain(the CD25 antigen, part of the three-component IL-2α receptorsite). These sites are expressed on the surfaces of activatedT lymphocytes. Once bound, it blocks the IL-2α receptor withextremely high affinity. This specific, high-affinity binding toIL-2 competitively inhibits IL-2-mediated activation of lymphocytes,a critical event in the cellular immune response inallograft rejection.
More▼▲
You can find basiliximab suppliers,
manufacturers, and distributors from countries such as China here.
Browse to the tetrahydrofuran product information displayed by the supplier,
as well as the supplier's contact and capability information.
